Characteristics of patients
| Patient . | n = 92 . |
|---|---|
| Median age at first sample collection (range) | 65 (45-82) |
| Sex, male (%) | 42 (46%) |
| Disease type at first sample collection | |
| Asymptomatic carrier | 3 (3%) |
| Smoldering | 11 (12%) |
| Chronic (favorable) | 5 (5%) |
| Chronic (unfavorable) | 8 (9%) |
| Lymphoma | 4 (4%) |
| Acute | 61 (66%) |
| Aggressive ATL at any point in time (%) | 81 (88%) |
| First systemic therapy for ATL | |
| VCAP-AMP-VECP | 44 (48%) |
| CHOP-like regimen | 15 (16%) |
| Mogamulizumab ± chemotherapy | 12 (13%) |
| Low-dose VP-16 | 2 (2%) |
| High-dose MTX + AraC | 1 (1%) |
| No systemic therapy for ATL | 14 (15%) |
| N/A∗ | 4 (4%) |
| Mogamulizumab administration | |
| Yes | 30 (33%) |
| No | 62 (67%) |
| Patient . | n = 92 . |
|---|---|
| Median age at first sample collection (range) | 65 (45-82) |
| Sex, male (%) | 42 (46%) |
| Disease type at first sample collection | |
| Asymptomatic carrier | 3 (3%) |
| Smoldering | 11 (12%) |
| Chronic (favorable) | 5 (5%) |
| Chronic (unfavorable) | 8 (9%) |
| Lymphoma | 4 (4%) |
| Acute | 61 (66%) |
| Aggressive ATL at any point in time (%) | 81 (88%) |
| First systemic therapy for ATL | |
| VCAP-AMP-VECP | 44 (48%) |
| CHOP-like regimen | 15 (16%) |
| Mogamulizumab ± chemotherapy | 12 (13%) |
| Low-dose VP-16 | 2 (2%) |
| High-dose MTX + AraC | 1 (1%) |
| No systemic therapy for ATL | 14 (15%) |
| N/A∗ | 4 (4%) |
| Mogamulizumab administration | |
| Yes | 30 (33%) |
| No | 62 (67%) |
AMP, doxorubicin, ranimustine, and prednisolone; AraC, cytarabine; CHOP, cyclophosphamide, vincristine, doxorubicin, and prednisolone; MTX, methotrexate; VCAP, vincristine, cyclophosphamide, doxorubicin, and prednisolone; VECP, vindesine, etoposide, carboplatin, and prednisolone; VP-16, etoposide.
N/A, not available: cases with unknown initial treatment details.